IRIS Accounts Production v25.2.0.378 13594965 Board of Directors 1.9.24 31.8.25 31.8.25 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh135949652024-08-31135949652025-08-31135949652024-09-012025-08-31135949652023-08-31135949652023-09-012024-08-31135949652024-08-3113594965ns15:EnglandWales2024-09-012025-08-3113594965ns14:PoundSterling2024-09-012025-08-3113594965ns10:Director12024-09-012025-08-3113594965ns10:PrivateLimitedCompanyLtd2024-09-012025-08-3113594965ns10:SmallEntities2024-09-012025-08-3113594965ns10:AuditExempt-NoAccountantsReport2024-09-012025-08-3113594965ns10:SmallCompaniesRegimeForDirectorsReport2024-09-012025-08-3113594965ns10:SmallCompaniesRegimeForAccounts2024-09-012025-08-3113594965ns10:FullAccounts2024-09-012025-08-311359496512024-09-012025-08-3113594965ns10:Director22024-09-012025-08-3113594965ns10:Director32024-09-012025-08-3113594965ns10:RegisteredOffice2024-09-012025-08-3113594965ns5:CurrentFinancialInstruments2025-08-3113594965ns5:CurrentFinancialInstruments2024-08-3113594965ns5:ShareCapital2025-08-3113594965ns5:ShareCapital2024-08-3113594965ns5:SharePremium2025-08-3113594965ns5:SharePremium2024-08-3113594965ns5:RetainedEarningsAccumulatedLosses2025-08-3113594965ns5:RetainedEarningsAccumulatedLosses2024-08-3113594965ns5:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3113594965ns5:PatentsTrademarksLicencesConcessionsSimilar2024-09-012025-08-3113594965ns5:IntangibleAssetsOtherThanGoodwill2024-08-3113594965ns5:IntangibleAssetsOtherThanGoodwill2025-08-3113594965ns5:IntangibleAssetsOtherThanGoodwill2024-08-3113594965ns5:PlantMachinery2024-08-3113594965ns5:PlantMachinery2024-09-012025-08-3113594965ns5:PlantMachinery2025-08-3113594965ns5:PlantMachinery2024-08-3113594965ns5:WithinOneYearns5:CurrentFinancialInstruments2025-08-3113594965ns5:WithinOneYearns5:CurrentFinancialInstruments2024-08-3113594965ns5:WithinOneYear2025-08-3113594965ns5:WithinOneYear2024-08-31
REGISTERED NUMBER: 13594965 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 AUGUST 2025

FOR

CELLVOYANT TECHNOLOGIES LIMITED

CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 August 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CELLVOYANT TECHNOLOGIES LIMITED

COMPANY INFORMATION
for the year ended 31 August 2025







DIRECTORS: R E Carazo Salas
K L Chong
O W Sims





REGISTERED OFFICE: C/o Origin Workspace
40 Berkeley Square
Bristol
United Kingdom
BS8 1HP





REGISTERED NUMBER: 13594965 (England and Wales)





ACCOUNTANTS: Magma Audit LLP
16 Davy Court
Castle Mound Way
Rugby, CV23 0UZ
Magma Audit LLP is part
Of the Dains Group

CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

BALANCE SHEET
31 August 2025

2025 2024
Notes £    £   
FIXED ASSETS
Intangible assets 4 15,524 17,611
Tangible assets 5 1,263,844 1,540,622
1,279,368 1,558,233

CURRENT ASSETS
Debtors 6 750,503 503,638
Investments 7 1,515,860 3,524,554
Cash at bank 207,372 685,801
2,473,735 4,713,993
CREDITORS
Amounts falling due within one year 8 (350,163 ) (145,456 )
NET CURRENT ASSETS 2,123,572 4,568,537
TOTAL ASSETS LESS CURRENT
LIABILITIES

3,402,940

6,126,770

CAPITAL AND RESERVES
Called up share capital 281 280
Share premium 9,024,649 9,024,649
Retained earnings (5,621,990 ) (2,898,159 )
3,402,940 6,126,770

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 2 December 2025 and were signed on its behalf by:





R E Carazo Salas - Director


CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 August 2025


1. STATUTORY INFORMATION

Cellvoyant Technologies Limited is a limited company, registered in England and Wales. Its registered office address is C/O Origin Workspace, 40 Berkeley Square, Bristol, BS8 1HP and the registered number is 13594965.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The presentation currency of the financial statements is pound sterling (£) and figures are rounded to the nearest £1.

Going concern
At 31 August 2025, the company had net current assets of £2,473,735 (2024: £4,713,993), net assets of £3,402,940 (2024: £6,126,770) but negative retained earnings of £5,621,990 (£2,898,159). The company is currently negotiating to renew funding into its continued research and development. The Directors have considered the various outcomes of this with reference to forecasts and deemed it reasonable that the financial statements are prepared on a going concern basis.

Turnover
Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of goods and services
Revenue from a contract to provide goods and services is recognised in the period in which the goods and services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Trademarks are being amortised evenly over their estimated useful life of nil years.

Intangble assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Trademarks are being amortised evenly over their estimated useful life of 10 years.

CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2025


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using a straight line method, as indicated below.

Depreciation is provided on the following basis:

Laboratory Equipment - 33% straight line
Computer Equipment - 33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Financial instruments
(i) Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest rate method.

(ii) Financial liabilities

Basic financial liabilities, including trade and other creditors are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Taxation
The tax expense for the year comprises current and deferred tax.

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:
- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Both current and deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Operating leases
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2025


2. ACCOUNTING POLICIES - continued

Cash and cash equivalents
Cash and cash equivalents are represented by cash in hand, deposits held at call with financial institutions, and other short-term highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 13 (2024 - 11 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 September 2024
and 31 August 2025 20,868
AMORTISATION
At 1 September 2024 3,257
Charge for year 2,087
At 31 August 2025 5,344
NET BOOK VALUE
At 31 August 2025 15,524
At 31 August 2024 17,611

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 September 2024 1,754,671
Additions 119,197
Disposals (1,999 )
At 31 August 2025 1,871,869
DEPRECIATION
At 1 September 2024 214,049
Charge for year 395,475
Eliminated on disposal (1,499 )
At 31 August 2025 608,025
NET BOOK VALUE
At 31 August 2025 1,263,844
At 31 August 2024 1,540,622

CELLVOYANT TECHNOLOGIES LIMITED (REGISTERED NUMBER: 13594965)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 August 2025


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 8,780 -
Other debtors 741,723 503,638
750,503 503,638

7. CURRENT ASSET INVESTMENTS
2025 2024
£    £   
JP Morgan LVNAV Dist 1,515,860 3,524,554

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 209,013 47,068
Taxation and social security 28,702 21,084
Other creditors 112,448 77,304
350,163 145,456

9. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2025 2024
£    £   
Within one year 52,958 -